China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large increase in short interest in May. As of May 15th, there was short interest totaling 6,460 shares, an increase of 97.9% from the April 30th total of 3,264 shares. Based on an average daily trading volume, of 23,541 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.7% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of brokerages recently issued reports on SXTC. Weiss Ratings cut shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, May 19th. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research report on Saturday, February 7th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, China SXT Pharmaceuticals currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Trading Down 1.7%

Shares of China SXT Pharmaceuticals stock traded down $0.03 during mid-day trading on Wednesday, reaching $1.75. 16,603 shares of the stock were exchanged, compared to its average volume of 196,289. China SXT Pharmaceuticals has a fifty-two week low of $1.25 and a fifty-two week high of $1,046.99. The firm has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $68.14.

Institutional Investors Weigh In On China SXT Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in China SXT Pharmaceuticals during the 3rd quarter worth about $78,000. Virtu Financial LLC grew its holdings in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after acquiring an additional 15,013 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in China SXT Pharmaceuticals during the 4th quarter worth about $36,000. Institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.